J4M-MC-PWMP: A Master Protocol for a Randomized, Controlled, Clinical Platform Trial to Investigate the Efficacy and Safety of Interventions for Chronic Weight Management in Pediatric Participants with Obesity or Overweight (ADVANCE) J4M-MC-PW01: Efficacy, Safety, and Pharmacokinetics of Orforglipron Once Daily Oral versus Placebo in Adolescent Participants Who Have Obesity, or Overweight with Weight-Related Comorbidities: A Randomized, Double-Blind Trial (ADVANCE-ATTAIN-ADOLESCENTS)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514081-40-00

Acronym

JAM-MC-PWMP, -PW01

Enrollment

Registered

2025-03-12

Start date

2025-06-06

Completion date

Unknown

Last updated

2025-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Overweight

Brief summary

Percent Change from Baseline in Body Mass Index (BMI) [Time Frame: Baseline, Week 72]

Interventions

DRUGOrforglipron

DRUGPlacebo to match LY3502970

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
Percent Change from Baseline in Body Mass Index (BMI) [Time Frame: Baseline, Week 72]	—

Countries

Italy, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026